Կանադա - ֆրանսերեն - Health Canada

novartis pharmaceuticals canada inc - ranibizumab - solution - 10mg - ranibizumab 10mg - eent drugs, miscellaneous

Բելգիա - ֆրանսերեն - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

glaxosmithkline pharmaceuticals sa-nv - valérate de bétaméthasone 1,21 mg/g - eq. bétaméthasone 1 mg/g - pommade - 0,1 % - valérate de bétaméthasone 1.21 mg/g - betamethasone

Եվրոպական Միություն - ֆրանսերեն - EMA (European Medicines Agency)

astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - maladie pulmonaire, chronique obstructive - les médicaments pour les maladies respiratoires obstructives, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.

Եվրոպական Միություն - ֆրանսերեն - EMA (European Medicines Agency)

teva b.v. - salmeterol xinafoate, propionate de fluticasone - asthme - les médicaments pour les maladies respiratoires obstructives, - bropair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Եվրոպական Միություն - ֆրանսերեն - EMA (European Medicines Agency)

teva b.v. - fluticasone propionate, salmeterol xinafoate - asthme - les médicaments pour les maladies respiratoires obstructives, - seffalair spiromax is indicated in the regular treatment of asthma in adults and adolescents aged 12 years and older not adequately controlled with inhaled corticosteroids and ‘as needed’ inhaled short-acting β₂ agonists.

Թունիս - ֆրանսերեն - Ministère de la Santé, Direction de l'inspection Pharmaceutique

glaxosmithkline (ireland) limited - fluticasone - spray nasal - 27.5 µg/pulvérisation - systeme respiratoire - medicaments pour le nez - avamys est indiqué cher les adultes, les adolescents et les enfants (à partir de 6 ans) avamys est indiqué dans le traitement des symptômes de la rhinite allergique.

Եվրոպական Միություն - ֆրանսերեն - EMA (European Medicines Agency)

astrazeneca ab - budesonide, formoterol fumarate dihydrate, glycopyrronium bromide - maladie pulmonaire, chronique obstructive - les médicaments pour les maladies respiratoires obstructives, - riltrava aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2 agonist or combination of a long-acting beta2 agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.

Եվրոպական Միություն - ֆրանսերեն - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - ophtalmologiques - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).

Եվրոպական Միություն - ֆրանսերեն - EMA (European Medicines Agency)

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophtalmologiques - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

Կանադա - ֆրանսերեն - Health Canada

septa pharmaceuticals inc - losartan potassique - comprimé - 25mg - losartan potassique 25mg - angiotensin ii receptor antagonists